Study of new immunosuppressive strategy and kinetics for ABO incompatible transplantation

在日本，移植物的短缺促使我们跨越ABO血液屏障进行活体供体肝移植（LDLT）。对于abo - 1受体，抗Ab抗体（Ab）的数量是决定治疗的重要因素。目前，抗Ab抗体的数量以凝集效价表示。我们开发了一种酶联免疫吸附试验（ELISA）来测量抗Ab抗体，并在本研究中评估其在临床实践中的实用性。在本报告中，我们描述了我们开发的一种新的ELISA，用于测量LDLT患者的抗组织血型Ab，它使用合成碳水化合物血型抗原。我们评估了ELISA测定的光密度（od）与凝集滴度之间的相关性，并考虑了在临床病例中使用ELISA的可能性。（Tohoku Journal Experimental Medicine, 211; 359-367,2007）并且“在另一项研究中，我们在101例LDLT患者中经历了9例接受血浆分离以消除同种异体抗体的患者。我们重点研究了采血作为体外免疫调节手段消除LDLT患者抗体的适应症和疗效。长期随访也进行了调查。（Therapeutic Apheresis and Dialysis; 11(5):319-32.4, 2007）综上所述，我们的ELISA方法可用于检测个体抗a /B抗体的变化，并有可能在临床病例中使用ELISA。

In Japan, the shortage of grafts has encouraged us to perform living donor liver transplantation (LDLT) across the ABO blood barrier. To decide the treatment for an ABO-I recipient, the amount of anti-AB antibody (Ab) is very important. At present, the quantity of anti-AB Ab is represented by the agglutination titer. We developed an enzyme linked immunosorbent assay (ELISA) to measure anti-AB Ab, and assessed its usefulness in clinical practice in this study.In this report, we describe a novel ELISA we have developed to measure anti-histo-blood group Ab in patients subjected to LDLT, which uses synthetic carbohydrate blood group antigens. We assessed the correlation between optical density (O.D.) determined by ELISA and agglutination titers, and considered the possibility of using ELISA in clinical cases. (Tohoku Journal of Experimental Medicine, 211; 359-367,2007) And'' in another study we experienced 9 recipients who underwent apheresis to eliminate allogeneic antibodies, out of 101 LDLT patients. We focused d on the indication and the efficacy of apheresis as extracorporeal immunomodulation for the elimination of antibodies in patients undergoing LDLT. The long-term follow-up was also investigated. (Therapeutic Apheresis and Dialysis; 11(5):319-32.4, 2007) In conclusion, our ELISA method is useful to detect changes in individually anti-A/B Ab and may have the possibility of using ELISA in clinical cases.